NHS
Web page
Dec 2023
For patients
The NHS overview of Crohn's: a lifelong condition where part of the gut becomes inflamed, with no cure yet but treatments that can control it. It lists the usual symptoms, explains that symptoms come and go in flare-ups and remissions, and says there is no single test, so diagnosis usually involves blood and poo tests from the GP followed by camera tests, biopsies and scans in hospital. It also covers possible causes (genes, smoking, a recent stomach bug, recent appendix removal) and when to get urgent help.
Topics
About Crohn's disease
Symptoms
Diagnosis and tests
Flare-ups
Diet and nutrition
Pregnancy and fertility
Living well
Complications
Medicines
Surgery
Jargon explained
inflammation
flare-up
remission
colonoscopy
endoscopy
biopsy
fistula
stricture
gastroenterologist
inflammatory bowel disease
anal fissure
perforation
nsaids
biologics
stoma
Crohn's & Colitis UK
Guide
Aug 2025
For patients
Covers looking after yourself after birth and deciding whether breastfeeding is right for you while on Crohn's medicines. It says most biologics are thought to be compatible with breastfeeding, but advice varies by medicine. If you took immune-lowering medicines during pregnancy, your baby's live vaccines may need to be delayed, so tell the baby's healthcare team. Non-live vaccines are thought to be safe.
Topics
Pregnancy and fertility
Medicines
Vaccinations and infections
Jargon explained
breastfeeding
biologics
live vaccine
postnatal
IBD Passport
Guide
Sep 2026
For patients
Evidence-based travel information for people with IBD: travelling with medicines, vaccinations, travel insurance, food and water safety, managing diarrhoea abroad and travelling with a stoma. It can also help you find specialist IBD care at your destination if you are away for a long time or on ongoing treatment.
Topics
Travel
Jargon explained
travel vaccinations
biologics
European Crohn's and Colitis Organisation (J Crohns Colitis)
Guideline
Oct 2024
For professionals
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics
Medicines
Biologics and newer medicines
Immunosuppressants
Around the bottom (perianal)
Jargon explained
biologic
immunomodulator
induction
maintenance
de-escalation
perianal fistula
GRADE
NICE
Guideline
Jul 2017
For professionals
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics
Biologics and newer medicines
Medicines
Jargon explained
interleukin inhibitor
TNF-alpha inhibitor
biological therapy
NHS
Web page
Aug 2026
For patients
The NHS medicine guide to adalimumab, listing brands such as Amgevita, Humira, Imraldi and Yuflyma. It explains that it treats autoimmune conditions including Crohn's disease, is usually started by a specialist after other medicines have not worked, and needs regular blood tests.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
autoimmune condition
biosimilar
Crohn's & Colitis UK
Guide
Jul 2023
For patients
A guide to risankizumab (Skyrizi), a biologic that blocks the IL-23 protein involved in inflammation. You start with a few drips, then have regular injections under the skin; the page explains trial results and side effects.
Topics
Biologics and newer medicines
Jargon explained
IL-23
interleukin
biologic
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
Royal Free London NHS Foundation Trust
Leaflet
Aug 2025
For patients
A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.
Topics
Biologics and newer medicines
Jargon explained
biologic
infusion
biosimilar
NICE
Guideline
May 2023
For professionals
NICE's appraisal recommending risankizumab (Skyrizi) for people aged 16 and over with moderate to severe Crohn's disease after a previous biologic has failed or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
biological treatment
NHS England
Web page
Patients and professionals
NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biosimilar
originator medicine
switching
Cochrane
Systematic review
Jun 2026
Patients and professionals
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics
Biologics and newer medicines
Research
Jargon explained
network meta-analysis
relative risk
number needed to treat
biosimilar